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Background: Cardiovascular disease (CVD) risk is substantially increased in subjects with chronic kidney disease
(CKD). The Triglycerides (TG) to High-Density Lipoprotein Cholesterol (HDL-C) ratio is an indirect measure of insulin
resistance and an independent predictor of cardiovascular risk. No study to date has been performed to evaluate
whether the TG/HDL-C ratio predicts CVD risk in patients with CKD.
Methods: A total of 197 patients (age 53 ± 12 years) with CKD Stages 1 to 5, were enrolled in this longitudinal,
observational, retrospective study. TG/HDL-C ratio, HOMA-IR indexes, serum asymmetric dimethyl arginine (ADMA),
high sensitivity C-reactive protein (CRP), parathyroid hormone (PTH), calcium, phosphorous, estimated glomerular
filtration rate (eGFR), and albumin levels were measured. Flow mediated vasodilatation (FMD) of the brachial artery
was assessed by using high-resolution ultrasonography.
Results: A total of 11 cardiovascular (CV) deaths and 43 nonfatal CV events were registered in a mean follow-up period
of 30 (range 9 to 35) months. Subjects with TG/HDL-C ratios above the median values (>3.29) had significantly higher
plasma ADMA, PTH, and phosphorous levels (p = 0.04, p = 0.02, p = 0.01 respectively) and lower eGFR and FMD values
(p = 0.03, p < 0.001 respectively). The TG/HDL-C ratio was an independent determinant of FMD (β = −0.25 p = 0.02)
along with TG, HDL-C, hsCRP, serum albumin, phosphate levels, systolic blood pressure, PTH, eGFR and the presence of
diabetes mellitus. The TG/HDL-C ratio was also a significant independent determinant of cardiovascular outcomes
[HR: 1.36 (1.11-1.67) (p = 0.003)] along with plasma ADMA levels [HR: 1.31 (1.13-1.52) (p < 0.001)] and a history of
diabetes mellitus [HR: 4.82 (2.80-8.37) (p < 0.001)].
Conclusion: This study demonstrates that the elevated TG/HDL-C ratio predicts poor CVD outcome in subjects
with CKD. Being a simple, inexpensive, and reproducible marker of CVD risk, the TG/HDL-C ratio may emerge as a
novel and reliable indicator among the many well-established markers of CVD risk in CKD.
Systematic review registration: Clinical trial registration number and date: NCT02113462 / 10-04-2014.
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Chronic kidney disease (CKD) is a major risk factor for
premature cardiovascular diseases (CVD) and mortality
[1] and a global public health problem [2]. Patients with
CKD frequently die from CVD before progressing to
end-stage renal disease (ESRD) [3]. The reasons for the
elevated risk of CVD in patients with CKD are not fully
elucidated. The classical Framingham risk factors do not
fully account for the increased CVD risk and other fac-
tors such as inflammation, oxidative stress, insulin resist-
ance and endothelial dysfunction are among the major
contributors to the increased CVD risk associated with
CKD [4-6]. However, none of the biomarkers of inflam-
mation, oxidative stress, endothelial dysfunction, vascu-
lar calcification or insulin resistance are good enough to
be used as prognostic tools [7]. A simple, widely avail-
able, relatively inexpensive, and generally reproducible
marker to predict the CVD risk in subjects with CKD is
needed.
The ratio of triglycerides (TG) to High Density Lipopro-
tein Cholesterol (HDL-C) is easily measured. Elevated
TG/HDL-C ratio it is an acknowledged marker of insulin
resistance and it is an independent predictor of cardio-
vascular risk [8-11]. The role of TG/HDL-C ratio in
predicting CVD risk has been tested in several meta-
bolic disorders such as diabetes mellitus, hypertension,
and nonalcoholic fatty liver disease (NAFLD) [12-15].
To our knowledge no study has been performed to esti-
mate the role of TG/HDL-C ratio in predicting CVD risk
in patients with CKD.
This study is designed to evaluate the relationship be-
tween TG/HDL-C ratio and endothelial functions in pa-
tients with CKD and to validate the role of TG/HDL-C
ratio in predicting CVD outcomes in these patients. In
order to comprehensively test if the TG/HDL-C ratio is
an independent predictor of CVD events, we adjusted for
several well-established risk factor covariates, including
flow mediated dilatation (FMD), asymmetric dimethyl ar-
ginine (ADMA), high sensitivity CRP, homeostasis model
of assessment (HOMA-IR), parathyroid hormone, serum
calcium, phosphorous and albumin levels in the COX re-
gression model.
Methods
Patients and study design
The ethical committee of Gulhane School of Medicine
(Etlik-Ankara, Turkey) approved the study, and informed
consent was obtained from each patient. Between January
2009 and January 2013, 644 patients were referred to the
Renal Unit of the Gulhane School of Medicine Medical
Center, Ankara, Turkey, because of suspected or manifest
CKD. All patients were diagnosed as having CKD accord-
ing to their estimated glomerular filtration rate (eGFR)
and/or the evidence of kidney disease such as proteinuriaor hematuria; a genetic diagnosis of kidney disease (e.g.
polycystic kidney disease); or evidence of structurally ab-
normal kidneys, as defined by the National Kidney Foun-
dation K/DQOI Guidelines [16]. By protocol, and in order
to minimize any confounding effects of conditions that
may influence endothelial dysfunction, 447 patients who
were taking drugs that may influence endothelial function
were excluded, including angiotensin converting enzyme
inhibitors (ACEIs; n = 111), angiotensin receptor blockers
(ARBs; n = 99), statins (n = 65), EPO (n = 18) or supple-
mental vitamin pills (n = 13). Otherwise, other exclusion
criteria including acute infections, and unwillingness to
participate in the study were applied (n = 40). One hundred
and one eligible patients dropped out for the following rea-
sons: lost to follow-up or transferred to other dialysis units
(n = 73), viral hepatitis (n = 5), vasculitis (n = 12), or with-
drew consent (n = 11). As a result, 197 patients with a
mean age of 53 ± 12 years were included in the study.
The characteristics of CKD subjects are given in
Table 1. Arterial blood pressures were measured by a
physician in the morning three consecutive times after a
15-min resting period, and mean values were calculated
for systolic and diastolic pressure in all patients.
Hypertension was defined as systolic blood pressure
(SBP) ≥140 mmHg or diastolic blood pressure (DBP) ≥
90 mmHg on repeated measurements, or the use of an-
tihypertensive drugs. Thirty-three of the patients were
on antihypertensive medications other than the renin
angiotensin aldosterone system blockers (17 patients
were treated with calcium channel antagonists, 5 with
beta-blocker agents, 8 with alpha blockers and 3 with
loop diuretics). At time of evaluation, forty-three of the
patients were on anti-diabetic therapy (13 patients
were treated with oral anti-diabetic agents and 30 with
insulin). As soon as diabetic nephropathy was diag-
nosed, all patients taking oral anti-diabetic medications
were transitioned to insulin. Forty six of these patients
(23%) had a history of CVD as defined by medical his-
tory and/or clinical findings at time of enrollment. Of
these 46 patients, 4 had suffered from cerebrovascular
accidents (stroke), 36 from cardiovascular disease
(acute myocardial infarction, angina pectoris or had
undergone coronary artery bypass surgery or percutan-
eous angioplasty); 6 had a history of peripheral ische-
mic atherosclerotic vascular disease and 1 patient had
a history of an aortic aneurysm. Smoking habits were
recorded as follows: whereas 87 patients were former
or current smokers, 110 were non-smokers. Patients’
CKD severity were classified with respect to eGFR
levels from stage 1 to 5 as determined by K/DOQI,
which was calculated according to the simplified ver-
sion of the Modification of Diet, in Renal Disease
(MDRD) formula as defined by Levy et al. [17] [GFR =
186 x Pcr-1.154 x age-0.203 x 1.212 (if black) x 0.742
Table 1 Demographic and clinical characteristics of the study patients as stratified to CKD stages
eGFR (ml/min/1.73 m2) ≥90 60-89 30-59 15-29 <15
Stage 1 Stage 2 Stage 3 Stage 4 Stage 5
(n = 39) (n = 40) (n = 39) (n = 37) (n = 42)
Age (years) 52 (30–73) 55 (32–71) 53 (31–73) 56 (33–73) 51 (30–73)
Sex (M/F) 20/19 19/21 19/20 20/17 21/21
BMI (kg/m2) 26.4 ± 2.3 26.8 ± 3.3 25.6 ± 2.8 26.2 ± 2.9 25.2 ± 2.6
History of CVD (n)
Fatal and nonfatal MI, acute coronary syndrome 5 6 8 10 7
Stroke 0 - 3 - 1
Peripheral vascular disease 1 1 1 2 1
Aortic aneurysm - - - - 1
Etiology of CKD (n)
Diabetes 6 10 7 12 8
Glomerulonephritis 6 7 7 5 6
Hypertension 5 8 7 6 7
Polycystic kidney disease 2 2 3 3 2
Reflux Nephropathy 2 1 2 1 2
Unknown 18 12 13 10 17
Smoking, current or former (n) 22 13 14 21 17
CV events (n) 7 10 8 13 16
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time-to-event analysis of cardiovascular outcomes, any
non-fatal cardiovascular event (stroke, myocardial in-
farction, complications of PVD and aneurysm rupture)
or death, whichever came first. Cardiovascular events
were assessed/adjudicated during follow-up visits. If
patients failed to follow-up, events were interrogated/
established via telephone interview.
Laboratory measurements
All samples were obtained in the morning after 12 hours
of fasting, for measurement of fasting plasma glucose
(FPG), serum albumin, total serum cholesterol (TC), TG,
HDL-C, low-density lipoprotein (LDL) cholesterol. TC
TG and HDL-C were measured by enzymatic colorimetric
method with Olympus AU 600 auto analyzer using re-
agents from Olympus Diagnostics, GmbH (Hamburg,
Germany). LDL cholesterol was calculated by Friedewald’s
formula [18]. For the measurement of hsCRP, serum sam-
ples were diluted with a ratio of 1/101 with the diluents
solution. Calibrators, kit controls and serum samples were
all added on each micro well with an incubation period of
30 minutes. After 3 washing intervals 100 μL enzyme con-
jugate (peroxidase labeled anti-CRP) was added on each
micro well for additional 15 minutes incubation in room
temperature in dark. The reaction was stopped with a stop
solution and photometric measurement was performed at
the 450 nm wavelength. The serum concentration wascalculated as mg/l with a graphic that was made by noting
the absorbance levels of the calibrators. The serum basal
insulin value was determined by the coated tube method
(DPC-USA). Insulin resistance score, HOMA-IR, was
computed by the following formula [19]: HOMA-IR = FPG
(mg/dL) x Immunoreactive insulin (IRI) (μIU/mL)/405.
Measurement of ADMA
ADMA is an endogenous inhibitor of the nitric oxide
production, a key chemical involved in normal endothe-
lial function and cardiovascular health. Measurement of
serum ADMA was done using high performance liquid
chromatography, as described by Chen et al. [20]. In
brief, to 1 ml serum, 20 mg of 5-sulfosalisilic acid (5-
SSA) was added and the mixture was left in an ice-bath
for 10 min. The precipitated protein was removed by
centrifugation at 2000 g for 10 min. Ten micro liters of
the supernatant which was filtered through a 0.2 μm fil-
ter was mixed with 100 μl of derivatization reagent (pre-
pared by dissolving 10 mg o-phtaldialdehyde in 0.5 ml of
methanol, 2 ml of 0.4 M borate buffer (pH 10.0) and
30 μl of 2-mercaptoethanol) and then injected into the
chromatographic system. Separation of ADMA was
achieved with a 150x4 mm I.D. Nova-pak C18 column
with a particle size of 5 μm (Waters, Millipore, Milford,
MA, USA) using 50 mM sodium acetate (pH 6.8),
methanol and tetrahydrofurane as mobile phase (A,
82:17:1; B, 22:77:1) at a flow-rate of 1.0 ml/min. The
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338 nm; Em: 425 nm) were used as quantification. The
variability of the method was less than 7%, and the de-
tection limit of the assay was 0.01 μM.
Vasoreactivity assessment
Flow mediated dilatation reflects the NO bioavailability to
the endothelium and is well determined by the serum
ADMA concentration [21]. Both FMD and endothelium-
independent vasodilatation (NMD) of the brachial artery
were assessed non-invasively, using high resolution ultra-
sonography as described by Celermajer et al. [22]. The
method for the vascular assessment met the criteria which
were mentioned by the International Brachial Artery Re-
activity Task Force [23]. Measurements were made by a
single observer using an ATL 5000 ultrasound system
(Advanced Technology Laboratories Inc., Bothell, WA.,
USA) with a 12-Mhz prob. The subjects remained at rest
in the supine position for at least 15 min before the exam-
ination started. The arm of a given patient was comfort-
ably immobilized in the extended position to allow
consistent recording of the brachial artery 2–4 cm above
the antecubital fossa. Three adjacent measurements of
end-diastolic brachial artery diameter were made from
single 2-D frames. All ultrasound images were recorded
on S-VHS videotape for subsequent blinded analysis. A
pneumatic tourniquet was inflated to 200 mmHg with ob-
literation of the radial pulse. After 5 minutes the cuff was
deflated. Flow measurements were made 60s post-
deflation. After a further 15 min, measurements were re-
peated and again 3 min after administration of sublingual
glyceryl trinitrate 400 μg. The maximum FMD and NMD
dilatation diameters were calculated as the average of the
three consecutive maximum diameter measurements. The
FMD and NMD were then calculated as the percent
change in diameter compared with baseline resting
diameters.
Statistical analysis
All the statistical analyses were performed by using SPSS
17.0 (SPSS Inc., Chicago, IL) statistical package. Non-
normally distributed variables were expressed as median
(range) and normally distributed variables were as mean
± SD, as appropriate. A p value <0.05 was considered to
be statistically significant. Between-group comparisons
were assessed for nominal variables with the Chi-square
test, and by Kruskal-Wallis test (ANOVA) for the
remaining variables. Spearman’s rank correlation was
used to determine correlations between paired vari-
ables. Stepwise multivariate regression analysis was
used to assess the predictors for FMD levels. Survival
and time-to-event analysis of cardiovascular outcomes
(using a composite of fatal and non-fatal events) wasdone using Cox proportional hazards model, including
adjustment for potential confounding factors.
We used a stepwise analysis in the multivariate COX
regression. In the SPSS program, the multivariate COX
analysis starts by inserting all the parameters which cor-
relate with CV events in the univariate analysis. Covari-
ates that do not contribute significantly to the adjusted
models are then eliminated in stepwise fashion. Data is
presented in the form of Hazard ratios (HR) and 95%
confidence intervals (CI).
Results
Cardiovascular outcomes were determined from the day
of examination onwards, with a mean follow-up period
of 30 (range 9 to 35) months. Thirteen patients died, 11
of which were due to cardiovascular causes, one due to
malignancy, and one due to infection. Cardiovascular
mortality (n = 11) was defined as death due to coronary
heart disease (n = 7), sudden death (n = 1), stroke (n = 2)
or complicated peripheral vascular disease (n = 1).
In addition to the 11 cardiovascular deaths, 43 non-fatal
cardiovascular events were registered during the follow-
up as follows: stroke (n = 14); myocardial infarction (n =
23); peripheral vascular disease (n = 4) and aortic
aneurysm (n = 2).
The demographic and clinical characteristics of the
study patients as stratified to CKD stages are given in
Table 1. The demographic and laboratory parameters,
stratified according to the median TG/HDL-C value
(3.29), are given in Table 2. The CKD distribution was
not significantly different according to the TG/HDL-C
groups. According to the results, plasma ADMA, PTH
and phosphorus levels were significantly higher (p =
0.04, p = 0.02, p = 0.01) and eGFR and FMD values were
significantly lower (p = 0.03, p < 0.001) in subjects with
the higher TG/HDL-C ratio.
The correlates of endothelial function in the study
group are investigated as the univariate and multivariate
associates of FMD (Table 3). The TG/HDL-C ratio was
an independent determinant of FMD (β = 0.25 p = 0.02)
together with the TG, HDL-C, hsCRP, serum albumin,
phosphate levels, SBP, PTH, eGFR and the presence of
diabetes mellitus.
The COX analysis was performed in order to establish
which covariates were independent predictors of cardio-
vascular outcomes (Table 4). The TG/HDL-C ratio [HR:
1.36 (1.11-1.67) (p = 0.003)], the plasma ADMA levels
[HR: 1.31 (1.13-1.52) (p < 0.001)] and the history of dia-
betes [HR: 4.82 (2.80-8.37) (p < 0.001)] are all significant
independent predictors of cardiovascular outcomes in
patients with CKD.
Kaplan Meier survival curves were generated to estab-
lish the impact of the TG/HDL-C ratio on the cumulative
survival of the cohort (Figure 1). We further analyzed the
Table 3 Univariate and multivariate associates of flow
mediated dilatation (FMD) in non-dialysis CKD patients
FMD
Parameters Univariate0 ρ Multivariate1 β (P)
ADMA (μmol/l) −0.58 (<0.001) NS
Total Cholesterol (mg/dl) −0.33 (<0.001) NS
Triglyceride (mg/dl) −0.19 (0.009) −0.22 (0.001)
LDL-cholesterol (mg/dl) −0.14 (0.06) NS
HDL-cholesterol (mg/dl) 0.37 (<0.001) 0.32 (<0.001)
Triglyceride/HDL-C ratio −0.34 (<0.001) −0.25 (0.02)
Total cholesterol/HDL-C ratio 0.30 (<0.001) NS
NMD (%) 0.45 (<0.001) 0.24 (<0.001)
Diabetes (yes/no) −0.21 (0.004) - 0.13 (0.001)
Previous CVD (yes/no) −0.07 (0.37) NS
hsCRP (mg/l) −0.57 (<0.001) −0.10 (0.03)
Smoking (yes/no) 0.04 (0.45) NS
SBP (mmHg) −0.23 (0.001) −0.10 (0.01)
DBP (mmHg) −0.20 (0.005) NS
HOMA-IR −0.19 (0.008) NS
Age (yr) −0.05 (0.45) NS
Gender (M/F) 0.03 (0.63) NS
S-albumin (g/dl) 0.26 (<0.001) 0.13 (0.02)
Serum calcium (mg/dl) 0.46 (<0.001) NS
Serum phosphate (mg/dl) −0.65 (<0.001) −0.13 (0.009)
iPTH (pg/ml) −0.60 (<0.001) −0.41 (<0.001)
eGFR (ml/min) 0.80 (<0.001) 0.40 (<0.001)
0Denoted is statistically significant (P < 0.05) ρ values as assessed by Spearman
Rank’s test, as well as β estimate and P value from multivariate regression
model. The r2 of the multivariate model was 0.76. Variables known to
influence FMD levels (age, gender. Diabetes (yes/no), ADMA, Previous CVD,
HOMA-IR, calcium, phosphate, SBP, DBP, hsCRP, NMD, albumin, iPTH, eGFR,
TG/HDL-C ratio are inserted in the multivariate analyses.
Table 2 The demographic and laboratory parameters of
CKD patients above and below median TG/HDL-C ratio
TG/HDL-C ratio TG/HDL-C ratio *P
value<3.29 >3.29
ADMA (μmol/l) 2.7 ± 1.6 3.2 ± 1.7 0.04
PTH (pg/ml) 122.5 ± 88.4 154.2 ± 101.1 0.02
eGFR (ml/min) 56.7 ± 33.4 46.6 ± 31.7 0.03
FMD (%) 7.2 ± 1.3 6.5 ± 1.2 <0.001
hsCRP (mg/l) 14.6 ± 7.8 16.0 ± 8.1 0.21
SBP (mmHg) 133.3 ± 8.2 136.1 ± 11.9 0.06
DBP (mmHg) 84.2 ± 4.4 84.5 ± 5.1 0.57
HOMA-IR 1.7 ± 0.7 1.8 ± 0.7 0.90
Age (years) 52 ± 12 54 ± 12 0.08
Gender (M/F) 51/47 50/49 0.89
BMI (kg/m2) 26.1 ± 2.8 26.2 ± 2.8 0.88
Total Cholesterol (mg/dl) 191.3 ± 23.9 201.2 ± 23.5 0.04
Triglyceride (mg/dl) 131.3 ± 15.8 150.5 ± 18.3 <0.001
LDL-cholesterol (mg/dl) 125.9 ± 16.4 129.6 ± 21.6 0.18
HDL-cholesterol (mg/dl) 47.1 ± 6.9 37.3 ± 6.2 <0.001
Triglyceride/HDL-C ratio 2.8 ± 0.4 4.2 ± 1.1 <0.001
Albumin (g/dl) 3.9 ± 0.3 4.0 ± 0.4 0.29
Calcium (mg/dl) 8.5 ± 0.6 8.4 ± 0.5 0.29
Phosphate (mg/dl) 4.9 ± 1.4 5.6 ± 1.7 0.01
NMD (%) 12.9 ± 0.6 12.7 ± 0.8 0.71
*Student’s t test.
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CKD stage for all-cause mortality and cardiovascular
events. In every CKD stage, a TG/HDL-C ratio above the
median increases the risk for cardiovascular events (p <
0.03).
Discussion
The results of the present study show that higher TG/
HDL-C ratios in the CKD patients are associated with
increased cardiovascular disease risk as shown by the el-
evated ADMA, PTH, phosphate and lower FMD and
eGFR levels. Also, the TG/HDL-C ratio appears to be a
significant determinant of the endothelial dysfunction
and a simple predictor of cardiovascular outcomes along
with the history of diabetes and high ADMA levels. The
implications of these findings are examined below.
Patients with CKD have significantly increased cardio-
vascular risk as they mostly die from CVD even before
the implementation of renal replacement therapy [1-3].
Neither the classical risk factors nor the novel ones fully
account for the increased risk of cardiac mortality in
CKD [4-7,24,25]. Likewise, although dyslipidemia is a
common feature of CKD, traditional lipid measures are
not good enough to predict cardiovascular outcomes inCKD patients [26,27]. The atherogenic lipid profile in
CKD mostly defines the qualitative problems [28]. The
impaired HDL configuration [29-32], increased serum
levels of remnant lipoproteins, small very low-density
and intermediate-density lipoproteins, and increased
small and dense LDL cholesterol subclass (sdLDL)
[28,33] are the features of atherogenic lipid profile in
CKD. Compared to the larger LDL subclasses, sdLDL
cholesterol is easily taken up by arterial tissue and is
much more prone to the oxidation [34-37]. The elevated
TG/HDL-C ratio reflects the presence of remnant lipo-
proteins and sdLDL levels [33,36], which play significant
role in the increased cardiovascular risk [34,35].
The role of TG/HDL–C ratio as a marker of insulin
resistance and a predictor for increased cardiovascular
risk has been validated in several chronic metabolic dis-
orders such as diabetes mellitus, hypertension, and non-
alcoholic fatty liver disease [9-15,38]. According to our
results elevated TG/HDL-C ratio is also significant
Table 4 Univariate and multivariate COX analysis predicting for cardiovascular outcomes
(a composite of 54 fatal and non-fatal events)
Crude analysis Terminal Model
ADMA (μmol/l) 1.36 (1.18-1.56) <0.001 1.31 (1.13-1.52) <0.001
TG/HDL-C ratio 1.56 (1.29-1.90) <0.001 1.36 (1.11-1.67) 0.003
History of Diabetes (Yes/No) 4.91 (2.85-8.44) <0.001 4.82 (2.80-8.37) <0.001
Represented are Hazard Ratios (and 95% confidence intervals) in univariate (crude) Cox model and after systematic adjustments. Saturated model at first step
include age (in years). Sex (women as reference). eGFR (in ml/min). hsCRP, FMD, calcium, phosphate, PTH, smoking, serum albumin, total cholesterol, triglyceride,
LDL-cholesterol, HDL-cholesterol, SBP, DBP, HOMA-IR, ADMA, diabetes (absence as reference) and medical history of cardiovascular disease (absence as reference)
at baseline.
FMD. Flow mediated dilatation; hsCRP. High sensitivity C reactive protein; eGFR. Estimated glomerular filtration rate.
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HDL-C ratio stands out as a significant predictor of cu-
mulative mortality among many other well-established
CVD risk factors such as age, blood pressure, HOMA-
IR, calcium, phosphorous, PTH, uric acid and albumin.
Regarding the high cardiovascular event rate, it is
highly important to early recognize the CKD patients
with higher risk and implement more intensive treat-
ment modalities. Current biochemical markers to de-
fine the CVD risk are not technically perfect or widely
available [39-41]. Furthermore, noninvasive tools of
measuring endothelial dysfunction such as the FMD,
carotid intima media thickness, or the ankle brachial
index are time consuming or user dependent. To our
knowledge, this is the first study to show that TG/
HDL-C ratio is an independent determinant of endo-
thelial dysfunction and a significant predictor for car-
diovascular outcome. The median TG/HDL-C ratio
established in this study is very similar to the previouslyFigure 1 Kaplan-Meier survival curves according to TG/HDL ratio <3.29 orreported cut off level of healthy people to predict the
sdLDL phenotype [10].
This study may have several potential limitations. Al-
though the TG/HDL-C ratio is a well-established correl-
ate of insulin sensitivity, the HOMA-IR levels of the
patients under and above the TG/HDL cut offs were not
different in this study. It may be due to the fact that the
HOMA index test is only a rough estimate of insulin
sensitivity and may not be as accurate as clamp testing,
or newer more accurate engines such as iHOMA-2 [42].
Owing to the observational nature of the study, some
unknown or unincluded factors might have had an im-
pact on cardiovascular endpoints. Also, the relatively
small number of the patients and a substantial amount
of subjects who were lost to follow up may be another
drawback. Moreover, the incidence of CV events may be
lower than expected, probably due to the fact that the
CKD-1 and CKD-2 subjects were enrolled in the cohort.
Finally, due to the exclusion of patients treated with≥3.29 at 30 months.
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pletely representative of the adult CKD population.
Conclusions
The results of the present study show that the elevated
TG/HDL-C ratio in CKD patients is a significant correlate
of the well-established cardiovascular risk factors, a deter-
minant of the endothelial dysfunction and a predictor of
the increased cardiovascular mortality and morbidity. Be-
ing a simple, inexpensive, and reproducible marker of
CVD risk, the TG/HDL-C ratio may be a novel and reli-
able predictor of CVD risk in subjects with CKD.
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